Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Clinical Trials

business update on portfolio programs

More Like This

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Participate in Upcoming Healthcare Conferences